Enhancing in vivo cell and tissue targeting by modulation of …
WEBMay 18, 2024 — The in vivo efficacy of polymeric nanoparticles (NPs) is dependent on their pharmacokinetics, including time in circulation and tissue tropism. Here we explore the structure-function...
Drug-loaded PEG-PLGA nanoparticles for cancer treatment
WEBAug 19, 2022 — In order to improve the properties of PLGA NPs and achieve long-term therapeutic effects, polyethylene glycol (PEG) has been conjugated with PLGA to construct a new type of amphiphilic block co-polymer nanoplatform, PEG-PLGA NPs.
Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti ...
WEBSep 23, 2020 — (A) Polyethylene glycol (PEG)-lipid functionalization of PLHNPs prolongs the systemic circulation in the reticuloendothelial system (RES), inhibition of phagocytic uptake, and polymer tailing for the functionalization of targeting ligands.
Stealth nanoparticles in oncology: Facing the PEG dilemma
WEBNov 1, 2022 — Nps coating using polymeric molecules, in particular Polyethylene glycol (PEG), became the most popular alternative since early 90s [[16], [17], [18]]. Indeed, pegylated Nps have demonstrated to extend significantly the time in circulation, providing tumor accumulation.
PLGA-based nanoparticles for the treatment of cancer: current ...
WEBAug 1, 2022 — The blood half-life of NPs can especially be increased by combining PLGA with other polymers like polyethylene glycol (PEG), polyvinyl alcohol (PVA), and D-α-tocopheryl PEG 1000 succinate (TPGS). Combining the polymer with PEG results in a stealth effect, preventing opsonization, NP escapes phagocytosis resulting in increased circulation time ...
PEGylation as a strategy for improving nanoparticle-based drug …
WEBApr 1, 2016 — Using a PEI/PEI-PEG blending strategy to increase PEG surface density without loss of particle stability, they formulated PEI-based DNA NPs with either highly dense PEG coatings (brain-penetrating, DNA-BPN), “conventional” lower density PEG coatings (DNA-CPN), or no PEG coating (uncoated, DNA-UPN).
pH-responsive high stability polymeric nanoparticles for targeted ...
WEBMar 3, 2020 — The NPs consist of a drug-loaded polylactic-co-glycolic acid (PLGA) core covalently ‘wrapped’ with a crosslinked bovine serum albumin (BSA) shell designed to minimize interactions with...
Formulation of tunable size PLGA-PEG nanoparticles for drug
WEBJun 18, 2021 — We performed surfactant-/stabilizer-free formulation of PLGA-PEG NPs in a microfluidic chip at different S and AS flow rates, and by a manual dropwise addition of the S to the AS phase at parallel volumes. We studied encapsulation efficiency of fluorescent molecules with different hydrophobicity.
Polymeric Nanoparticles for Drug Delivery | SpringerLink
WEBJan 1, 2010 — Drug release rates from the polymeric NPs can be controlled by modifying polymer chemical and physical properties. In this chapter, we describe the preparation and characterization of prostate cancer-targeted PLGA-b-PEG NPs as a model controlled-release drug delivery platform. We functionalized the NPs using the A10 2'-fluoropyrimidine ...
Anti-HER2 PLGA-PEG polymer nanoparticle containing gold
WEBMar 18, 2021 — In this study, we report on the development of targeted phase-transition polymeric nanoparticles (NPs) for the imaging and treatment of breast cancer cell lines over-expressing human epidermal growth factor receptor 2 (HER2).
Skip to content